Defining Criteria for Guiding Cancer Patients to Find a Reputable Complementary Medicine Provider: Results of a Literature Review and a Consensus Procedure.

complementary medicine healthcare quality assurance neoplasms patient-centered care standards

Journal

Patient preference and adherence
ISSN: 1177-889X
Titre abrégé: Patient Prefer Adherence
Pays: New Zealand
ID NLM: 101475748

Informations de publication

Date de publication:
2020
Historique:
received: 11 09 2019
accepted: 14 02 2020
entrez: 6 5 2020
pubmed: 6 5 2020
medline: 6 5 2020
Statut: epublish

Résumé

Even in cases of positive evidence for complementary medicine (CM) therapies, it is still difficult for cancer patients to identify reputable providers. The aim of this study was to develop and evaluate a criteria list to provide guidance to cancer patients seeking a reputable CM provider. The design combined a literature review, an expert consensus procedure (n=15) and an assessment from three stakeholder perspectives (patients (n=18), CM providers (n=26) and oncology physicians (n=20)). A total of 30 existing CM criteria were extracted from the literature, and 12 more were added by the experts. The main challenge was to define criteria that could easily be applied by the patients. A final comprehensive list of 8 criteria guiding cancer patients to find a reputable CM provider was developed. Health professionals and cancer information services might find the criteria list helpful when aiming to strengthen patients' awareness of quality-related factors associated with CM providers. The criteria developed might be helpful when standards are established for quality assurance in CM in oncology.

Identifiants

pubmed: 32368016
doi: 10.2147/PPA.S230705
pii: 230705
pmc: PMC7183350
doi:

Types de publication

Journal Article

Langues

eng

Pagination

747-755

Informations de copyright

© 2020 Rogge et al.

Déclaration de conflit d'intérêts

Patrick Jahn reports grants, personal fees from Chugai, personal fees from Bristol-Myers Squibb, non-financial support from Helsinn, non-financial support from Tesaro, outside the submitted work. Petra Voiß reports grants from Carstens-Stiftung, during the conduct of the study. Claudia M. Witt reports personal fees, non-financial support from Several Swiss Hospitals, outside the submitted work. The authors report no other conflicts of interest in this work.

Références

Trials. 2019 Jan 29;20(1):90
pubmed: 30696465
Integr Cancer Ther. 2012 Sep;11(3):187-203
pubmed: 22019489
Ann Intern Med. 2017 Apr 4;166(7):514-530
pubmed: 28192789
Integr Cancer Ther. 2018 Sep;17(3):844-853
pubmed: 29629606
Forsch Komplementmed. 2016;23(3):174-8
pubmed: 27404102
Acta Oncol. 2017 Dec;56(12):1665-1676
pubmed: 28686520
Health Technol Assess. 1998;2(3):i-iv, 1-88
pubmed: 9561895
JAMA Oncol. 2018 Oct 1;4(10):1375-1381
pubmed: 30027204
Cochrane Database Syst Rev. 2017 Jan 03;1:CD010802
pubmed: 28045199
J Clin Oncol. 2018 Sep 1;36(25):2647-2655
pubmed: 29889605

Auteurs

Alizé A Rogge (AA)

Institute for Social Medicine, Epidemiology, and Health Economics, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Isabel Baur (I)

Legal Institute, Competence Center Medicine - Ethics - Law Helvetiae, University of Zurich, Zurich, Switzerland.

Gabriele Blettner (G)

Deutsche Krebshilfe, INFONETZ KREBS, Bonn, Germany.

Ulrike Holtkamp (U)

German Leukemia & Lymphoma Patients' Association, Bonn, Germany.

Markus Horneber (M)

Department of Internal Medicine, Division of Oncology and Hematology, Paracelsus Medical University, Klinikum Nuremberg, Nuremberg, Germany.

Patrick Jahn (P)

Department for Nursing Science, Institute for Health Science, Medical Faculty, Eberhard Karls University Tübingen, Tübingen, Germany.

Stefanie Joos (S)

Institute for General Practice and Interprofessional Health Care, University Clinic Tübingen, Tübingen 72076, Germany.

Silva Keberle (S)

Eskamed AG, Basel, Switzerland.

Anita Kettelgerdes (A)

TK - Techniker Krankenkasse, Hamburg, Germany.

David Klemperer (D)

Faculty of Social and Health Sciences, Ostbayerische Technische Hochschule Regensburg, Regensburg., Germany.

Alfred Längler (A)

Gemeinschaftskrankenhaus Herdecke, Institute of Integrative Medicine, Witten/Herdecke University, Herdecke, Germany.

Petra Voiß (P)

Department of Internal and Integrative Medicine, Evang. Kliniken Essen-Mitte, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany.
Gynaecological Clinic, Städtisches Klinikum Karlsruhe gGmbH, Karlsruhe, Germany.

Joachim Weis (J)

Department of Self-Help Research, Comprehensive Cancer Center University Clinic Freiburg, Freiburg i.Br., Germany.

Claudia M Witt (CM)

Institute for Social Medicine, Epidemiology, and Health Economics, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Institute for Complementary and Integrative Medicine, University of Zurich and University Hospital Zurich, Zurich, Switzerland.
Center for Integrative Medicine, University of Maryland School of Medicine Baltimore, Baltimore, Maryland.

Classifications MeSH